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thrombotic agent should have high site-specific activity for
the thrombogenic area on the vessel and low systemic
effects on coagulation.1
Tissue factor pathway inhibitor (TFPI) is an endoge-
nous protease inhibitor of the extrinsic pathway of the
coagulation cascade, which is initiated by tissue factor.
TFPI directly inhibits the tissue factor VIIa complex and
factor Xa.9,10 Animal experiments have documented the
antithrombotic effects of topically applied TFPI.11-13
Administration of TFPI after balloon angioplasty has been
shown to reduce restenosis and intimal hyperplasia.14-16
The effect of TFPI on small arterial grafts has rarely
been studied. We previously showed that topically applied
TFPI prevents thrombotic occlusion of traumatized arte-
rial autografts in the early postoperative period (7 days).17
This study investigated whether topically applied TFPI
reduces intimal thickness and increases long-term patency
of small arterial autografts in rabbits. We also examined
whether topically applied TFPI binds to endothelial cells
of the grafts.
METHODS
Animal study. Forty-nine male New Zealand white
rabbits weighing 2.5 to 3.5 kg were used in this study. All
animal care complied with the “Principles of Laboratory
Animal Care” formulated by the National Society for
Medical Research and the Guide for the Care and Use 
of Laboratory Animals (NIH Publication No. 86-23,
revised 1985). The study protocol was approved by the
Kumamoto University Animal Care Committee. The full
Thrombosis and intimal hyperplasia have been impli-
cated as major causes of graft failure in small arterial recon-
structive procedures. Vessel dissection and anastomosis
produce iatrogenic endothelial trauma, resulting in the
exposure of subendothelial tissue, which initiates throm-
botic processes.1 Intimal hyperplasia is a complex process
involving smooth muscle cells, platelets, leukocytes,
endothelial cells, growth factors, mechanical injury, hemo-
dynamic factors, and other unknown factors.2,3 The rela-
tion between thrombus formation and intimal hyperplasia
is complex and only partially understood.
Antithrombotic agents, such as heparin and hirudin,
reduce intimal hyperplasia after artery angioplasty in
minipig models.4,5 Clinical studies have shown that these
agents fail to prevent restenosis after coronary artery bal-
loon angioplasty.6,7 The high dosage levels used in animal
experiments cause bleeding complications in human
beings, which is clinically unacceptable.8 The ideal anti-
151
From the First Department of Surgery, Kumamoto University School of
Medicine.
Competition of interest: nil.
Presented at the 100th Annual Congress of the Japan Surgical Society,
Tokyo, Japan, Apr 12-14, 2000.
Reprint requests: Ling-Bo Sun, MD, First Department of Surgery,
Kumamoto University School of Medicine, 1-1-1 Honjo, Kumamoto
City, Kumamoto 860-0811, Japan (e-mail: sun@kaiju.medic.kumamoto-
u.ac.jp).
Copyright © 2001 by The Society for Vascular Surgery and The American
Association for Vascular Surgery.
0741-5214/2001/$35.00 + 0 24/1/113307
doi:10.1067/mva.2001.113307
Topically applied tissue factor pathway inhibitor
reduced intimal thickness of small arterial
autografts in rabbits
Ling-Bo Sun, MD, Junichi Utoh, MD, PhD, Shuji Moriyama, MD, Hirofumi Tagami, MD, Ken
Okamoto, MD, and Nobuo Kitamura, MD, PhD, Kumamoto, Japan
Purpose: The purpose of this study was to investigate whether topically applied tissue factor pathway inhibitor (TFPI)
reduces intimal thickness and increases long-term patency of small arterial autografts in rabbits.
Methods: An entire 10-mm long section of the left femoral artery was harvested and immersed in saline solution (con-
trol group, n = 10), 100 IU/mL of heparin (heparin group, n = 15), or 40 µg/mL of TFPI (TFPI group, n = 15) for
15 minutes. Then the graft was interposed to the right femoral artery. Patency rates were determined by flow mea-
surements throughout the time course of the study, and the grafts were analyzed for measurement of intimal thickness
at 3 months after operation. Immunohistochemical analysis was performed to examine whether topically applied TFPI
binds to endothelial cells of the grafts.
Results: Three-month postoperative patency rates were 10% in the control group, 47% in the heparin group, and 73%
in the TFPI group. The TFPI group had a significantly higher patency rate than that of the control group (P < .005).
Compared with the heparin group, the TFPI group had a significant reduction in intimal area (0.19 ± 0.05 mm2 vs
0.30 ± 0.09 mm2, P = .0051), in percentage of stenosis (35.7% ± 7.7% vs 61.4% ± 15.8%, P < .0001), and in inti-
mal/media areas ratio (0.64 ± 0.24 vs 1.04 ± 0.33, P = .0051). Immunohistologic analyses confirmed that topically
applied TFPI bound to endothelial cells.
Conclusion: These results indicate that topically applied TFPI reduces intimal thickness and increases long-term patency
of small arterial autografts in rabbits. (J Vasc Surg 2001;34:151-5.)
length of recombinant TFPI used in this study was a gift
from the Chemo-Sero-Therapeutic Research Institute,
Kumamoto, Japan.
All rabbits were anesthetized with an intravenous
injection of sodium pentobarbital (30 mg/kg body
weight). An entire 10-mm long section of the left
femoral artery was harvested and stored in either saline
solution (control group, n = 10), saline solution with
100 IU/mL heparin (heparin group, n = 15), or saline
solution with 40 µg/mL TFPI12,17-20 (TFPI group, n =
15). Fifteen minutes later, the right femoral artery was
exposed, and an autograft was implanted. A standard
end-to-end anastomosis was performed with 10 stitches
of 10-0 nylon suture. Before placement of the last two
stitches, test solution 1 mL was injected into the lumen
of the graft. Five minutes later, all clamps were removed,
and blood flow was restored. After bleeding was con-
trolled, the wound was closed. After surgery, animals
were fed a standard diet without anticoagulants or
antiplatelet agents. Animals were randomized to receive
either TFPI or heparin or saline solution. Surgeries were
performed by the same operator (L.B.S.) to minimize
variability between groups.
Immunohistochemical analysis. The entire 10-mm-
long section of the femoral artery was harvested and
immersed at room temperature in either TFPI 40 µg/mL,
heparin 100 IU/mL, or saline solution for 15, 30, or 45
minutes, respectively (n = 2 for each group and each time
point). The grafts were rinsed with saline solution, immedi-
ately embedded in optimal cutting temperature compound
(Miles Inc, Elkhart, Ind), and frozen in liquid nitrogen for
frozen section analysis. Immunostaining was performed
with a modified avidin-biotin complex method.18 Sections
5 µm thick were mounted on polylysine-coated slides, fixed
in acetone at –4° C for 10 minutes, and then preincubated
in phosphate-buffered saline solution (PBS, pH 7.4) con-
taining 0.3% hydrogen peroxide for 10 minutes to quench
endogenous peroxidase activity. After being washed with
PBS, the sections were blocked with guinea pig serum,
incubated with guinea pig antihuman TFPI polyclonal anti-
body (provided by Chemo-Sero-Therapeutic Research
Institute, Kumamoto, Japan), and diluted to 40 µg/mL in
PBS for 1.5 hours at room temperature (PBS and guinea
pig normal serum were used as negative controls). The sec-
tions were covered with biotinylated goat anti–guinea pig
immunoglobulin G antibody solution (Sigma Chemical Co,
St Louis, Mo) for 1 hour at room temperature. Antibody
binding was visualized by treatment with 3,3´-diaminoben-
zidine. The sections were counterstained with Mayer’s
modified hematoxylin.
Patency, histologic study, and morphometry. The
patency of grafts was examined with an A-Model Doppler
flowmeter (Smart Doppler ES-1000SP, Hayashi Denki Co
Ltd, Japan) at 1 hour after operation and then weekly.
After 3 months, the animals were anesthetized, and the
patency of the grafts was assessed visually. Animals were
then killed and perfusion fixed in situ at a pressure of 100
mm Hg with an initial infusion of heparinized saline solu-
tion (100 IU/L) followed by 10% buffered formalin.
Then grafts were harvested, fixed in formalin, and embed-
ded in paraffin. Five sections, which were taken from the
middle region of the grafts, were stained with hema-
toxylin-eosin and elastin van Gieson to identify the elastic
laminae. All sections were analyzed with computer image
analysis software (NIH image 1.5) for morphometric mea-
surement of intimal thickness and area, medial area, and
luminal area. Data were evaluated with averaging mea-
surements from the five sections.
Statistical analysis. Data are expressed as mean ± SD.
Patency rates between the groups were compared by use
of the Fisher exact test. Between groups, differences of
intimal thickness and area, medial area, and luminal diam-
eters were compared with the unpaired Student t test.
Differences were considered significant at P < .05.
RESULTS
Patency. All grafts were patent at 1 hour after opera-
tion. Overall patency rates are shown in Fig 1. After 1
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Fig 1. Overall patency rates. TFPI group had significantly higher
patency rate than that of control group at 1 month, 2 months,
and 3 months after operation. Asterisk, P < .05 versus control;
pound sign, P < .005 versus control. TFPI, Tissue factor pathway
inhibitor.
Results of histologic examination
Normal* Heparin TFPI
IEL diameter (mm) 0.77 ± 0.04 0.82 ± 0.05 0.84 ± 0.09
EEL diameter (mm) 1.02 ± 0.02 1.02 ± 0.09 1.05 ± 0.07
Luminal area (mm2) 0.46 ± 0.03 0.19 ± 0.08† 0.34 ± 0.10
Percent stenosis (%) — 64 ± 11 36 ± 7.7‡
Intimal area (mm2) — 0.30 ± 0.09 0.19 ± 0.05§
Medial area (mm2) 0.34 ± 0.05 0.28 ± 0.10 0.31 ± 0.05
IA/MA ratio (%) — 104 ± 33 64 ± 24§
*Normal femoral artery.
†P < .001 vs normal or TFPI. 
‡P < .001 vs heparin.
§P = .0051 vs heparin.
IEL, Internal elastic lumina; EEL, external elastic lumina; IA, intimal area;
MA, medial area.
month, the patency rates were 60% (6 of 10 grafts) in the
control group and 87% (13 of 15 grafts) in the heparin
group. No TFPI-treated graft was occluded during the
same period (P < .05 vs control). At 2 months, patency
rates were 40% in the control group (4 of 10 grafts), 73%
in the heparin group (11 of 15 grafts), and 87% in the
TFPI group (13 of 15 grafts) (TFPI vs control, P < .05).
Three-month postoperative patency rates were 10% (1 of
10 grafts) in the control group, 47% (7 of 15 grafts) in the
heparin group, and 73% (11 of 15 grafts) in the TFPI
group. The TFPI group had a significantly higher patency
rate than that of the control group (P < .005). The TFPI-
treated grafts had a higher patency rate than that of the
heparin-treated grafts (73% vs 47%), but the difference
was not statistically significant (P = .264).
Histologic examinations. Results of histologic ex-
aminations are shown in the Table. Three preimplant
grafts were studied as a normal control. In the TFPI group
the luminal areas were significantly larger than that of the
heparin group. Intimal areas of the TFPI group were sig-
nificantly smaller than that of the heparin group (Fig 2).
Medial areas were similar between the groups. The inti-
mal/medial area ratio was significantly lower in the TFPI
group than in the heparin group.
Representative photomicrographs of histologic cross
sections are shown in Fig 3. In the TFPI-treated grafts
(Fig 3, A), intima was thin, smooth, and covered by a layer
of endothelial cells. In contrast, the heparin-treated grafts
(Fig 3, B) had a thicker intima and a coarse surface.
Localization of TFPI in graft. Staining with an anti-
human TFPI polyclonal antibody detected that TFPI was
localized to endothelial cells and that adventitia of grafts
occurred after 15 minutes immersion (Fig 4). TFPI was
absent in heparin-treated grafts and saline solution–treated
grafts. Increasing the immersion period to 45 minutes did
not change the results.
DISCUSSION
In vascular surgery, thrombus formation and intimal
hyperplasia are serious problems. Topically applied TFPI is
reported to prevent thrombosis formation without any
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effects on systemic coagulation such as prothrombin time
or activated partial thromboplastin time.12 Our study
showed that topically applied TFPI reduces intimal thick-
ness of small arterial autografts in rabbits.
The exposure of subendothelial tissue during vessel
dissection and anastomosis initiates thrombotic processes.
One of the thrombogenic elements is tissue factor, which
exists in subendothelial tissue and adventitia. Dumanian et
al20 showed that TFPI reduced vessel wall tissue factor
activity. Other studies have shown that topically applied
TFPI has antithrombogenic effects in microvascular anas-
tomosis and in balloon-induced artery injury models.11-13
In our study, a 100% patency rate was observed in the
TFPI group at 1 month after operation; this might be due
to the antithrombogenic effects of TFPI.
The mechanism by which topically applied TFPI
reduces intimal hyperplasia is not specifically addressed in
this study. Several hypotheses have been raised to explain
the mechanism: (1) Thrombin promotes intimal hyperpla-
sia through a direct mitogenic effect on smooth muscle
cell proliferation.21-23 Previous studies have reported that
Fig 2. Comparison of changes in intimal and medial areas
between TFPI-treated grafts and heparin-treated grafts after 3
months. *P = .0051 versus heparin. TFPI, Tissue factor pathway
inhibitor.
Fig 3. Cross sections of TFPI-treated graft (A) and heparin-
treated graft (B) 3 months after implantation. Both sections were
taken from middle region of grafts. Note differences in intima
thickness and luminal surface between two groups. IN, Intima;
M, media; IEL, internal elastic lumina; EEL, external elastic
lumina. (Elastin van Gieson; original magnification ×100.)
significant thrombin activity is present on intact and anas-
tomosed segments of arteries24 and that TFPI can reduce
thrombin activity.20 (2) Platelets play an important role in
intimal hyperplasia. Topically applied TFPI reduces
platelet aggregation on the injured intimal surface after
balloon angioplasty or intimectomy.15,20 (3) Factor Xa
stimulates mitogenesis in cultured blood vessels.25,26 TFPI
directly inhibits factor X.9 Han et al27 found that inhibit-
ing factor VII/TF with TFPI has better effects on intimal
hyperplasia than inhibiting factor Xa alone. (4) Smooth
muscle cell proliferation is a key event in intimal hyperpla-
sia. In an in vitro study, TFPI directly inhibits prolifera-
tions of cultured human aortic smooth muscle cells.28
Obviously, more work needs to be done to understand the
mechanism of reduction in intimal hyperplasia with TFPI.
The timing of the therapeutic intervention may be an
important factor to prevent intimal thickness. Thrombo-
genicity of vascular anastomosis is maximal during the first
30 minutes after blood flow restoration.29,30 Coating the
injured surface with TFPI before exposure to circulating
blood may have preventive effects. Heparin lacks anticoagu-
lative effects without antithrombin III. Some studies have
shown that thrombin becomes resistant to heparin/
antithrombin III when it binds to the surface of the vessel
wall.31
It is very important to determine whether TFPI could
bind to graft by just “immersion.” Lantieri et al12 and
Ornberg et al32 have reported that topically applied TFPI
binds to the injured surface. The results of our immuno-
histochemical analysis confirm that topically applied TFPI
could bind to the endothelial cells and adventitia. We did
not examine the duration of TFPI binding to the surface
of arterial grafts. Lantieri et al12 observed that with local
irrigation, TFPI binds to the intimal arterial surface for at
least 3 days after operation.
On the basis of our previous studies, we chose the
TFPI concentration of 40 µg/mL.17 Other studies have
demonstrated that TFPI at 40 µg/mL completely inhib-
ited tissue factor activity,20 and patency was similar
between low dose (10-40 µg/mL) and high dose (125-
250 µg/mL).12 We chose 15 minutes for incubating grafts
because it is acceptable in clinical practice and is enough
time for TFPI to bind to the endothelium of grafts.
These results indicate that topically applied TFPI
reduces intimal thickness and increases long-term patency
of small arterial autografts in rabbits. We think that inhibi-
tion of the initial step of thrombus formation at the early
phase may reduce intimal proliferation at the late phase.
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